(NASDAQ: NBTX) Nanobiotix Sa's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Nanobiotix Sa's revenue in 2025 is -$7,990,000.On average, 3 Wall Street analysts forecast NBTX's revenue for 2025 to be $956,267,597, with the lowest NBTX revenue forecast at $345,741,744, and the highest NBTX revenue forecast at $1,754,793,487. On average, 3 Wall Street analysts forecast NBTX's revenue for 2026 to be $2,711,677,633, with the lowest NBTX revenue forecast at $508,890,111, and the highest NBTX revenue forecast at $4,423,976,661.
In 2027, NBTX is forecast to generate $1,399,566,373 in revenue, with the lowest revenue forecast at $254,207,921 and the highest revenue forecast at $2,544,924,825.